Letters by company
Axon Enterprise, INC.
9 letters discussing AXON. Everything written about it on this site is on its ticker page.
- Carillon Eagle — Mid Cap Growth Fund Commentary Third Quarter 2026 Carillon Eagle Mid Cap Growth Fund favored Natera, Cloudflare, Snowflake, Twilio and Everpure as enterprise AI demand, diagnostics adoption and cloud infrastructure spending supported their outlooks. The portfolio modestly reduced cyclical exposure amid higher rates and energy prices, while retaining conviction in Dycom, RB Global, Viking, Carpenter Technology and Axon despite near-term pressures. Third Quarter 2026 AXON $25BCRS $14BDY $6.7B
- Brown Advisory — Large-Cap Growth Large-Cap Growth Review and Outlook The Large-Cap Growth Strategy kept portfolio activity limited after repositioning software exposure toward businesses where AI can enhance customer value and long-term growth. It argues that diversification remains important as the Russell 1000 Growth Index becomes increasingly concentrated in semiconductors, while retaining conviction in cloud, cybersecurity, AI software and industrial holdings. third quarter 2026 ANET $249BAXON $25BCDNS $89B
- Cedar Grove Capital Management Q3’2026 Cedar Grove increased gross leverage and added Zedcor, OneSpaWorld and Auxly while closing several special-situation and biotech holdings. The portfolio argues that Evolv Technologies and The RealReal retain improving operating fundamentals despite rate-driven valuation pressure, with recurring revenue and marketplace efficiency as the central theses. Q3 2026 EVLV $707MABVX $7.7BAXON $25B
- Nightview Capital Q1 2026 Investor Letter Nightview Fund exited casino, hospitality, China and several legacy technology positions, then rotated into enterprise software and selected infrastructure businesses. The fund argues that AI strengthens deeply embedded platforms such as Axon, ServiceNow, Shopify and Autodesk, while retaining Tesla and NVIDIA as core AI and robotics holdings. Q1 2026 ADSK $55BAXON $25BNOW $106B
- Sands Capital — Select Growth Fund Fund Manager Commentary The Touchstone Sands Capital Select Growth Fund shifted toward a more balanced allocation between AI infrastructure suppliers and cloud providers as cloud operating results improved and compute demand remained constrained. It initiated Palantir for enterprise AI exposure and exited Axon and Ultragenyx after reassessing their relative opportunities and risks. 3Q/2026 —
- Heptagon Capital Future Trends Equity Fund Q3 2026 Commentary Future Trends added Align Technology, exited Novo Nordisk and Xylem, and increased Nextpower, Axon Enterprise and Siemens Energy after weakness. The fund argues that earnings momentum, guidance upgrades and lower valuation multiples support its concentrated growth holdings, while the Novo sale reinforces earlier action when company evidence deteriorates. Q3 2026 ALGN $12BASML $576BGALDY $53B
- Nightview Capital Q2 2026 Investor Letter Nightview Capital added to Salesforce and ServiceNow, initiated Atlassian, and held Autodesk steady on the view that systems of record, switching costs, distribution and AI integration protect strong software franchises. It exited Meta, Intuitive Surgical, Shopify and EchoStar, added gaming and hospitality exposure, and rotated financials toward BlackRock and Charles Schwab. Q2 2026 ADSK $55BCRM $179BLVS $25B
- Infuse Asset Management Q4 2025 Letter Infuse Partners exited Intellego after its financing, revenue recognition and factoring disclosures undermined the investment thesis, followed by the CEO’s arrest for gross fraud. The portfolio added Duolingo and argued for Nu Holdings, Sanuwave, TransMedics and MercadoLibre on scalable operating models, durable engagement or widening competitive advantages. Q4 ‘25 DUOL $7.8BMELI $76BNU $61B
- Andrew Hill Investment Advisors 2024.Q3 Client Letter Andrew Hill Investment Advisors kept portfolios overweight utilities and industrials on rising electricity demand from AI, with Constellation Energy remaining the largest holding. The firm eliminated EQT, increased Chipotle after its selloff, added Axon and United Therapeutics, and continued building high-quality bond ladders while trimming some equities. 2024.Q3 CEG $97BLLY $1.3TMSFT $3.9T